Effect of methyl eugenol on nasal mucosal aquaporin 5 in rats with allergic rhinitis.
- Author:
Nan WU
1
;
Xiu Li ZHANG
1
;
Yun HOU
2
;
Li Xing LIN
3
;
Xiao Bing ZHANG
2
Author Information
1. The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China.
2. Department of Otolaryngology, The First Affiliated of Lanzhou University, Lanzhou 730000, China.
3. Pediatrics, The First Affiliated of Lanzhou University, Lanzhou 730000, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Aquaporin 5;
Eugenol/analogs & derivatives*;
Nasal Mucosa;
Rats;
Rats, Wistar;
Rhinitis, Allergic
- From:
Journal of Peking University(Health Sciences)
2019;51(6):1036-1041
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the effect of methyl eugenol on the expression of aquaporin (AQP) 5 in nasal mucosa of rats with allergic rhinitis and to explore its significance.
METHODS:In the study, 128 Wistar rats were randomly divided into normal control group, AR model control group, budesonide positive control group, 80 mg/kg group, 40 mg/kg group, 20 mg/kg group and 10 mg/kg group, and ovalbumin (OVA) was used to establish the model of allergic rhinitis. After successful modeling, castor oil, budesonide and corresponding doses of methyl eugenol were given respectively. After 1, 2 and 4 weeks of administration, the distribution of AQP5 in nasal mucosa was observed by immunohistochemistry. The expression of AQP5 in nasal mucosa of each group was compared by Western blotting. The expression of AQP5 mRNA was compared with real-time PCR.
RESULTS:AQP5 was mainly located in the glandular epithelium and ductal epithelial cell membrane and cytoplasm. The expression of AQP5 and AQP5 mRNA in nasal mucosa of the rats in the model control group was lower than that in the normal control group (P<0.05). AQP5 and AQP5 mRNA in nasal mucosa of the rats in each treatment group were higher than those in the model control group in varying degrees. The expression of AQP5 in the budesonide group was not significantly different from that in the normal control group 1, 2 and 4 weeks after drug intervention (P>0.05), but there was significant difference between the budesonide group and the model control group (P<0.05). The expression of AQP5 mRNA in the budesonide group was significantly different from that in the normal control group and the model control group (P<0.05).After 2 weeks of intervention, the expression of AQP5 in each dose group of methyleugenol was not significantly different from that in the budesonide group (P>0.05). After 1 week of intervention, there was no significant difference in AQP5 mRNA between the 20 mg/kg group and the normal control group (P>0.05), but there was significant difference between the 20 mg/kg group and the model control group (P<0.05).
CONCLUSION:Methyl eugenol may increase the degree of edema of the nasal mucosa by reducing the expression of AQP5 and reduce the secretion of glands, thus alleviating the symptoms of allergic rhinitis, sneezing and runny nose.
